國家衛生研究院 NHRI:Item 3990099045/6839
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 923553      線上人數 : 710
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6839


    題名: Pharmacoeconomic analysis of capecitabine for advanced gastric cancer in Taiwan
    作者: Chang, C;Chao, Y;Chen, J;Chen, L;Chuang, C;Hsieh, R;Hwang, W;Yang, L;de Reydet, F
    貢獻者: National Institute of Cancer Research
    摘要: Background: Capecitabine combined with cisplatin (XP) is a safe and effective alternative to intravenous 5-fluorouracil plus cisplatin (FP) in previously untreated patients with advanced and metastatic gastric cancer (AGC). The objective of this pharmacoeconomic analysis was to access the cost-effectiveness of XP versus FP for AGC treatment from Taiwan societal perspective. Methods: A cost-minimization analysis was undertaken by applying clinical outcomes and medical resource utilization (MRU) retrieved from phase III ML17032 study. Direct medical costs associated with trial-based MRU were based on Taiwan's National Health Insurance fee schedule for 2007. Costs associated with intravenous chemotherapy administration and adverse event (AE) management were estimated by an expert panel survey conducted among 12 oncologists. From a societal perspective, direct non-medical and indirect costs borne by patients, such as travel and time costs, were also considered. One-way sensitivity analyses were performed on key model parameters by varying the input values by ? 10%. Results: A trend toward superior progression-free survival was observed in XP arm (median 5.6 months for XP versus 5.0 for FP). Compared to FP, administration of XP required fewer consults per patient (5.2 for XP versus 22.8 for FP). Chemotherapy drug cost was higher (USD$1,712) in the XP arm; however, these cost increments were offset by differences of chemotherapy administration costs (USD$4,376) between two arms. AE profiles were similar and the costs associated with grade 3/4 AE management were slightly lower (USD$30) in the XP arm. Taking into account direct medical costs (chemotherapy administration and AE management), direct non- medical cost (travel), and indirect cost (time), XP was associated with a significant cost saving of USD$5,310 (NTD$172,197). XP remained cost-saving under one-way sensitivity analyses. Conclusions: Given the trend to superior efficacy, the significant cost savings, and the convenience of oral treatment, XP would be a dominant (less costly and more effective) regimen for AGC from the Taiwan societal perspective. Replacing FP by XP would not only reduce health care expenditures but also improve health outcomes in Taiwan.
    日期: 2008-05
    關聯: Journal of Clinical Oncology. 2008 May;26(15):Abstract number 15576.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/15576?sid=ae9b11fa-452f-4968-ac67-a442e5a7b352
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000208457401490
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000208457401490.pdf49KbAdobe PDF235檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋